C. L. Beach

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Hervé Dombret, John F. Seymour, Aleksandra Butrym et al. · Blood · 2015 · 1.1K citations · Full text

Medicine, Geriatric Medicine, Pharmacotherapy +2

Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B

Lewis R. Silverman, David R. McKenzie, Bercedis L. Peterson et al. · Journal of Clinical Oncology · 2006 · 553 citations

Medicine, Pharmacology, Pharmacotherapy +13

Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis

John Koreth, Joseph Pidala, Waleska S. Pérez et al. · Journal of Clinical Oncology · 2013 · 284 citations · Full text

Medicine, Geriatric Medicine, Hematology +17

Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes

Roger M. Lyons, Thomas M. Cosgriff, Sanjiv Modi et al. · Journal of Clinical Oncology · 2009 · 272 citations

Medicine, Pharmacology, Pharmacotherapy +17

Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic Syndromes

Guido Marcucci, Lewis R. Silverman, Mark G. Eller et al. · The Journal of Clinical Pharmacology · 2005 · 149 citations

Medicine, Pharmacokinetics, Pharmacology +14